RAVE (2010) — Trial Summary
RAVE (2010): Rituximab was as effective as cyclophosphamide for the induction of remission in severe ANCA-associated vasculitis, with a similar safety profile during the first 6 months of treatment.
References
- Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232.